Other · developed by BeOne Medicines
BG-T0050 is an investigational agent administered subcutaneously.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07881211 | Phase 1 | Diffuse Large B-Cell Lymphoma | Not yet recruiting | ONC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-Cell MalignanciesDiffuse Large B-Cell Lymphoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the ONC page.
See ONC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ONC catalysts and pipeline →